Skip to main content
Top
Published in: Inflammation Research 7/2013

01-07-2013 | Original Research Paper

Dynamic changes of peritoneal macrophages and subpopulations during ulcerative colitis to metastasis of colorectal carcinoma in a mouse model

Authors: Wei Wang, Xiayu Li, Danwei Zheng, Decai Zhang, Shuo Huang, Xuemei Zhang, Feiyan Ai, Xiaoyan Wang, Jian Ma, Wei Xiong, Yanhong Zhou, Guiyuan Li, Shourong Shen

Published in: Inflammation Research | Issue 7/2013

Login to get access

Abstract

Objective and design

Patients with ulcerative colitis have increased risk of colorectal carcinoma, but little is known about how peritoneal macrophages are involved in ulcerative colitis-associated carcinogenesis. We investigated the alteration of peritoneal macrophages and M1/M2 subpopulations during ulcerative colitis-associated carcinogenesis.

Materials and methods

Expression and functional changes in peritoneal macrophages and M1/M2 subpopulations were investigated by histopathology, flow cytometry, immunofluorescence, cytokines expression by ELISA and QRT-PCR in an azoxymethane (AOM)- and dextran sodium sulfate (DSS)-induced chemical colitis-associated carcinoma mouse model using male Crj:CD-1 (ICR) mice.

Results

Striking evidence observed in histopathology, flow cytometry, cytokine detection, and gene expression analysis all revealed that inflammation-associated cytokines (IL-1β, IL-10, IL-12, IL-6, TNF-α) and migration/invasion-associated factors (G-CSF, GM-CSF, CXCR4, VEGF, TGF-β, ICAM-1) induced by peritoneal M2 macrophages increased significantly during the progression from inflammatory hyperplasia to carcinoma and metastasis. Similar functional changes occurred during peritoneal metastasis in M1 macrophages without changed polarization.

Conclusions

These results suggested that peritoneal M2 macrophages played a critical role in ulcerative colitis-associated carcinogenesis, including unbalanced pro-inflammatory and anti-inflammatory axis and enhanced expression of migration/invasion-associated factors. Furthermore, functional changes of M1 macrophages occurred without changed polarization during carcinogenesis and metastasis.
Appendix
Available only for authorised users
Literature
2.
go back to reference Rod R. Crohn’s disease and ulcerative colitis: morbidity and mortality. Health Rep. 1990;2:343–59. Rod R. Crohn’s disease and ulcerative colitis: morbidity and mortality. Health Rep. 1990;2:343–59.
3.
go back to reference Loftus EV. J Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–17.PubMedCrossRef Loftus EV. J Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504–17.PubMedCrossRef
4.
go back to reference Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.PubMedCrossRef Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.PubMedCrossRef
5.
go back to reference Hanauer S. Inflammatory bowel disease: epidemiology, pathogenesis and therapeutic opportunities. Inflamm Bowel Dis. 2006;12:S3–9.PubMedCrossRef Hanauer S. Inflammatory bowel disease: epidemiology, pathogenesis and therapeutic opportunities. Inflamm Bowel Dis. 2006;12:S3–9.PubMedCrossRef
6.
go back to reference Lakatos L, Mester G, Erdelyi Z, et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis. 2006;12:205–11.PubMedCrossRef Lakatos L, Mester G, Erdelyi Z, et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis. 2006;12:205–11.PubMedCrossRef
7.
go back to reference Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008;14:3937–47.PubMedCrossRef Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008;14:3937–47.PubMedCrossRef
8.
9.
go back to reference Gong W, Lv N, Wang B, et al. Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study. Dig Dis Sci. 2012;57:503–7.PubMedCrossRef Gong W, Lv N, Wang B, et al. Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study. Dig Dis Sci. 2012;57:503–7.PubMedCrossRef
10.
go back to reference Zisman TL, Rubin DT. Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol. 2008;14:2662–9.PubMedCrossRef Zisman TL, Rubin DT. Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol. 2008;14:2662–9.PubMedCrossRef
11.
12.
go back to reference Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.PubMedCrossRef Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.PubMedCrossRef
13.
go back to reference Bollrath J, Phesse TJ, von Burstin VA, et al. gp130-Mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumor genesis. Cancer Cell. 2009;15:91–102.PubMedCrossRef Bollrath J, Phesse TJ, von Burstin VA, et al. gp130-Mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumor genesis. Cancer Cell. 2009;15:91–102.PubMedCrossRef
14.
go back to reference Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15:103–13.PubMedCrossRef Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell. 2009;15:103–13.PubMedCrossRef
15.
go back to reference Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–57.PubMedCrossRef Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–57.PubMedCrossRef
16.
17.
go back to reference Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol. 2008;14:378–89.PubMedCrossRef Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol. 2008;14:378–89.PubMedCrossRef
18.
go back to reference Bar-On L, Zigmond E, Jung S. Management of gut inflammation through the manipulation of intestinal dendritic cells and macrophages? Semin Immunol. 2011;23:58–64.PubMedCrossRef Bar-On L, Zigmond E, Jung S. Management of gut inflammation through the manipulation of intestinal dendritic cells and macrophages? Semin Immunol. 2011;23:58–64.PubMedCrossRef
19.
go back to reference Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–69.PubMedCrossRef Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8:958–69.PubMedCrossRef
20.
go back to reference Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011;11:750–61.PubMedCrossRef Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol. 2011;11:750–61.PubMedCrossRef
21.
go back to reference Martinez FO, Sica A, Mantovani A, et al. Macrophage activation and polarization. Front Biosci. 2008;1:453–61.CrossRef Martinez FO, Sica A, Mantovani A, et al. Macrophage activation and polarization. Front Biosci. 2008;1:453–61.CrossRef
22.
go back to reference Sica A, Schioppa T, Mantovani A, et al. Tumor associated macrophages are a distinct M2 polarised population promoting tumor progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42:717–27.PubMedCrossRef Sica A, Schioppa T, Mantovani A, et al. Tumor associated macrophages are a distinct M2 polarised population promoting tumor progression: potential targets of anti-cancer therapy. Eur J Cancer. 2006;42:717–27.PubMedCrossRef
23.
go back to reference Bailey C, Negus R, Morris A, et al. Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metast. 2007;24:121–30.CrossRef Bailey C, Negus R, Morris A, et al. Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metast. 2007;24:121–30.CrossRef
24.
go back to reference Solinas G, Germano G, Mantovani A, et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065–73.PubMedCrossRef Solinas G, Germano G, Mantovani A, et al. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol. 2009;86:1065–73.PubMedCrossRef
25.
go back to reference Green CE, Liu T, Montel V, et al. Chemoattractant signaling between tumor cells and macrophages regulated cancer cell migration, metastasis and neovascularization. PLoS ONE. 2009;4:e6713.PubMedCrossRef Green CE, Liu T, Montel V, et al. Chemoattractant signaling between tumor cells and macrophages regulated cancer cell migration, metastasis and neovascularization. PLoS ONE. 2009;4:e6713.PubMedCrossRef
26.
go back to reference Wirtz S, Neufert C, Weigmann B, et al. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2:541–6.PubMedCrossRef Wirtz S, Neufert C, Weigmann B, et al. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2:541–6.PubMedCrossRef
27.
go back to reference Cooper HS, Murthy SN, Shah RS, et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993;69:238–49.PubMed Cooper HS, Murthy SN, Shah RS, et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993;69:238–49.PubMed
28.
go back to reference Clapper ML, Cooper HS, Chang WC. Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions. Acta Pharmacol Sin. 2007;28:1450–9.PubMedCrossRef Clapper ML, Cooper HS, Chang WC. Dextran sulfate sodium-induced colitis-associated neoplasia: a promising model for the development of chemopreventive interventions. Acta Pharmacol Sin. 2007;28:1450–9.PubMedCrossRef
29.
go back to reference Lai CS, Tsai ML, Cheng AC, et al. Chemoprevention of colonic tumorigenesis by dietary hydroxylated polymethoxyflavones in azoxymethane-treated mice. Mol Nutr Food Res. 2011;55:278–90.PubMedCrossRef Lai CS, Tsai ML, Cheng AC, et al. Chemoprevention of colonic tumorigenesis by dietary hydroxylated polymethoxyflavones in azoxymethane-treated mice. Mol Nutr Food Res. 2011;55:278–90.PubMedCrossRef
30.
go back to reference Tang A, Li N, Li X, et al. Dynamic activation of the key pathways: linking colitis to colorectal cancer in a mouse mode. Carcinogenesis. 2012;33:1375–83.PubMedCrossRef Tang A, Li N, Li X, et al. Dynamic activation of the key pathways: linking colitis to colorectal cancer in a mouse mode. Carcinogenesis. 2012;33:1375–83.PubMedCrossRef
31.
32.
go back to reference Lutgens MW, Vleggaar FP, Schipper ME, et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut. 2008;57:1246–51.PubMedCrossRef Lutgens MW, Vleggaar FP, Schipper ME, et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut. 2008;57:1246–51.PubMedCrossRef
33.
go back to reference Forssell J, Oberg A, Henriksson ML, et al. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res. 2007;13:1472–9.PubMedCrossRef Forssell J, Oberg A, Henriksson ML, et al. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res. 2007;13:1472–9.PubMedCrossRef
34.
35.
go back to reference Mantovani A. Inflammation and cancer: the macrophage connection. Medicina. 2007;67:32–4. Mantovani A. Inflammation and cancer: the macrophage connection. Medicina. 2007;67:32–4.
36.
go back to reference Erreni M, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenviron. 2011;4:141–54.PubMedCrossRef Erreni M, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenviron. 2011;4:141–54.PubMedCrossRef
37.
go back to reference Moriya M, Harada T, Shirasu Y. Inhibition of carcinogenicities of 1,2-dimethylhydrazine and azoxymethane by pyrazole. Cancer Lett. 1982;17:147–52.PubMedCrossRef Moriya M, Harada T, Shirasu Y. Inhibition of carcinogenicities of 1,2-dimethylhydrazine and azoxymethane by pyrazole. Cancer Lett. 1982;17:147–52.PubMedCrossRef
38.
go back to reference Sugie S, Mori Y, Okumura A, et al. Promoting and synergistic effects of chrysazin on 1,2-dimethylhydrazine-induced carcinogenesis in male ICR/CD-1 mice. Carcinogenesis. 1994;15:1175–9.PubMedCrossRef Sugie S, Mori Y, Okumura A, et al. Promoting and synergistic effects of chrysazin on 1,2-dimethylhydrazine-induced carcinogenesis in male ICR/CD-1 mice. Carcinogenesis. 1994;15:1175–9.PubMedCrossRef
40.
go back to reference Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008;267:204–15.PubMedCrossRef Sica A, Allavena P, Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett. 2008;267:204–15.PubMedCrossRef
41.
go back to reference Imtiyaz HZ, Williams EP, Hickey MM, et al. Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest. 2010;120:2699–714.PubMedCrossRef Imtiyaz HZ, Williams EP, Hickey MM, et al. Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest. 2010;120:2699–714.PubMedCrossRef
42.
go back to reference Low-Marchelli JM, Ardi VC, Vizcarra EA, et al. Twist1 induces CCL2 and recruits macrophages to promote angiogenesis. Cancer Res. 2013;73:662–71.PubMedCrossRef Low-Marchelli JM, Ardi VC, Vizcarra EA, et al. Twist1 induces CCL2 and recruits macrophages to promote angiogenesis. Cancer Res. 2013;73:662–71.PubMedCrossRef
Metadata
Title
Dynamic changes of peritoneal macrophages and subpopulations during ulcerative colitis to metastasis of colorectal carcinoma in a mouse model
Authors
Wei Wang
Xiayu Li
Danwei Zheng
Decai Zhang
Shuo Huang
Xuemei Zhang
Feiyan Ai
Xiaoyan Wang
Jian Ma
Wei Xiong
Yanhong Zhou
Guiyuan Li
Shourong Shen
Publication date
01-07-2013
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 7/2013
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-013-0619-y

Other articles of this Issue 7/2013

Inflammation Research 7/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine